Program
Losartan
Also written as “losartan potassium”, “Amlodipine plus Losartan” and “Losartan (COZZAR®)”.
Its studies are mostly in Hypertension · Essential Hypertension · Diabetes Mellitus, Type 2 · Proteinuria · Heart Failure, led by 11 companies.
Drug pageLosartan: every studyMany companies study it; this page follows only the 41 they lead. All 240 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Organonits history only | 120 open or running | phase 4since Aug 30, 2005 | Aug 25, 2004 | none ahead |
| Hanmi Pharmaceuticalits history only | 80 open or running | phase 3since Jul 14, 2009 | Jul 14, 2009 | none ahead |
| Merckits history only | 60 open or running | phase 3since Apr 14, 2009 | Feb 27, 2009 | none ahead |
| Torrent Pharmaceuticalsits history only | 40 open or running | phase 1since Oct 7, 2010 | Oct 7, 2010 | none ahead |
| Hikma Pharmaceuticalsits history only | 30 open or running | no phasesince Apr 9, 2010 | Apr 9, 2010 | none ahead |
| Laboratorios Silanes S.A. de C.V.its history only | 20 open or running | phase 3since Jun 8, 2021 | Jun 8, 2021 | none ahead |
| Teva Pharmaceutical Industriesits history only | 20 open or running | phase 1since May 13, 2010 | May 13, 2010 | none ahead |
| Azidus Brasilits history only | 10 open or running | phase 1since Sep 21, 2012 | Sep 21, 2012 | none ahead |
| InVasc Therapeuticsits history only | 10 open or running | phase 4since Jan 5, 2011 | Jan 5, 2011 | none ahead |
| Medtronicits history only | 10 open or running | early phase 1since Jul 21, 2008 | Jul 21, 2008 | none ahead |
| Pharmtechnology | 10 open or running | phase 1since Feb 27, 2018 | Feb 27, 2018 | none ahead |
Also a collaborator on its studies: Reliance Life Sciences Private.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Pharmtechnology only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Feb 27, 2018First study: phase 1 study in HealthyFirst studyNCT03459911 · 66 enrolled · India
TargetBeta
“Type-1 angiotensin II receptor antagonist”ChEMBL 37, by rule
Other programs on AGTR1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Valsartanrule | Novartis | phase 4 | 145 |
| Telmisartanrule | Boehringer Ingelheim | phase 4 | 132 |
| azilsartan medoxomilrule | Takeda | phase 4 | 25 |
| sparsentanrule | travere-therapeutics-inc | phase 4 | 9 |
Studies
The one study Pharmtechnology leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT03459911Healthy · India | 1 | Completed | Mar 11, 2018 | 66 |
How it is read
Names in the registry
- “losartan potassium”, 10 entries
- “Losartan”, 8 entries
- “Amlodipine plus Losartan”, 5 entries
- “Losartan (COZZAR®)”, 2 entries
- “Experimental: Sacubitril/Allisartan and Amlodipine Group”, 2 entries
Codes read as this program: MK0954.
Conditions, from the studies’ own filings
- Hypertension, 34 studies
- Essential Hypertension, 5 studies
- Diabetes Mellitus, Type 2, 2 studies
- Proteinuria, 1 study
- Heart Failure, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.